Q linea AB - Asset Resilience Ratio

Latest as of December 2025: 69.82%

Q linea AB (QLINEA) has an Asset Resilience Ratio of 69.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See QLINEA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr258.11 Million
≈ $27.78 Million USD Cash + Short-term Investments

Total Assets

Skr369.67 Million
≈ $39.78 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Q linea AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see QLINEA current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Q linea AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Q linea AB strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr258.11 Million 69.82%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr258.11 Million 69.82%

Asset Resilience Insights

  • Very High Liquidity: Q linea AB maintains exceptional liquid asset reserves at 69.82% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Q linea AB Industry Peers by Asset Resilience Ratio

Compare Q linea AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
Medical Devices 0.84%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 34.37%
Stratec SE
XETRA:SBS
Medical Devices 0.29%
Shinhung
KO:004080
Medical Devices 4.17%
DRTECH Corporation
KQ:214680
Medical Devices 5.18%
Novacyt
PA:ALNOV
Medical Devices 0.02%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.48%

Annual Asset Resilience Ratio for Q linea AB (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Q linea AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 69.82% Skr258.11 Million
≈ $27.78 Million
Skr369.67 Million
≈ $39.78 Million
+52.48pp
2024-12-31 17.34% Skr25.66 Million
≈ $2.76 Million
Skr147.99 Million
≈ $15.93 Million
-17.98pp
2023-12-31 35.33% Skr81.95 Million
≈ $8.82 Million
Skr231.98 Million
≈ $24.96 Million
+0.08pp
2022-12-31 35.24% Skr73.09 Million
≈ $7.87 Million
Skr207.39 Million
≈ $22.32 Million
-0.34pp
2021-12-31 35.58% Skr166.03 Million
≈ $17.87 Million
Skr466.63 Million
≈ $50.22 Million
-38.86pp
2020-12-31 74.45% Skr306.89 Million
≈ $33.03 Million
Skr412.23 Million
≈ $44.36 Million
+19.30pp
2019-12-31 55.15% Skr206.48 Million
≈ $22.22 Million
Skr374.41 Million
≈ $40.29 Million
-38.43pp
2018-12-31 93.58% Skr504.44 Million
≈ $54.29 Million
Skr539.07 Million
≈ $58.01 Million
+57.77pp
2017-12-31 35.81% Skr6.59 Million
≈ $708.97K
Skr18.40 Million
≈ $1.98 Million
--
pp = percentage points

About Q linea AB

ST:QLINEA Sweden Medical Devices
Market Cap
$37.11 Million
Skr344.87 Million SEK
Market Cap Rank
#23105 Global
#434 in Sweden
Share Price
Skr18.20
Change (1 day)
+2.25%
52-Week Range
Skr14.85 - Skr33.15
All Time High
Skr176.50
About

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more